140 related articles for article (PubMed ID: 26073080)
1. ErbB3 upregulation by the HNSCC 3D microenvironment modulates cell survival and growth.
Humtsoe JO; Pham E; Louie RJ; Chan DA; Kramer RH
Oncogene; 2016 Mar; 35(12):1554-64. PubMed ID: 26073080
[TBL] [Abstract][Full Text] [Related]
2. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
[TBL] [Abstract][Full Text] [Related]
3. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
4. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
[TBL] [Abstract][Full Text] [Related]
5. ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas.
Silva SD; Cunha IW; Younes RN; Soares FA; Kowalski LP; Graner E
Oral Dis; 2010 Nov; 16(8):774-80. PubMed ID: 20604875
[TBL] [Abstract][Full Text] [Related]
6. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
Bruzzese F; Leone A; Rocco M; Carbone C; Piro G; Caraglia M; Di Gennaro E; Budillon A
J Cell Physiol; 2011 Sep; 226(9):2378-90. PubMed ID: 21660961
[TBL] [Abstract][Full Text] [Related]
7. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
Secades P; de Santa-María IS; Merlo A; Suarez C; Chiara MD
Head Neck; 2015 Aug; 37(8):1150-62. PubMed ID: 24798801
[TBL] [Abstract][Full Text] [Related]
8. Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC.
Zhang K; Jones L; Lim S; Maher CA; Adkins D; Lewis J; Kimple RJ; Fertig EJ; Chung CH; Van Tine BA; Ellis MJ; Herrlich A; Michel LS
Oncotarget; 2014 Oct; 5(19):9281-94. PubMed ID: 25238142
[TBL] [Abstract][Full Text] [Related]
9. Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma.
Redlich N; Robinson AM; Nickel KP; Stein AP; Wheeler DL; Adkins DR; Uppaluri R; Kimple RJ; Van Tine BA; Michel LS
Cell Death Dis; 2018 Jan; 9(1):5. PubMed ID: 29305574
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and Notch1 in head neck squamous cell carcinoma.
Wang WM; Zhao ZL; Ma SR; Yu GT; Liu B; Zhang L; Zhang WF; Kulkarni AB; Sun ZJ; Zhao YF
PLoS One; 2015; 10(2):e0119723. PubMed ID: 25723392
[TBL] [Abstract][Full Text] [Related]
11. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
[TBL] [Abstract][Full Text] [Related]
12. Characterization of ten newly-derived human head and neck squamous carcinoma cell lines with special reference to c-erbB proto-oncogene expression.
O-Charoenrat P; Rhys-Evans P; Eccles S
Anticancer Res; 2001; 21(3B):1953-63. PubMed ID: 11497283
[TBL] [Abstract][Full Text] [Related]
13. Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness.
Jokilehto T; Rantanen K; Luukkaa M; Heikkinen P; Grenman R; Minn H; Kronqvist P; Jaakkola PM
Clin Cancer Res; 2006 Feb; 12(4):1080-7. PubMed ID: 16489060
[TBL] [Abstract][Full Text] [Related]
14. Increase in gene dosage is a mechanism of HIF-1alpha constitutive expression in head and neck squamous cell carcinomas.
Secades P; Rodrigo JP; Hermsen M; Alvarez C; Suarez C; Chiara MD
Genes Chromosomes Cancer; 2009 May; 48(5):441-54. PubMed ID: 19235921
[TBL] [Abstract][Full Text] [Related]
15. MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling.
Ngan HL; Liu Y; Fong AY; Poon PHY; Yeung CK; Chan SSM; Lau A; Piao W; Li H; Tse JSW; Lo KW; Chan SM; Su YX; Chan JYK; Lau CW; Mills GB; Grandis JR; Lui VWY
Life Sci Alliance; 2020 Jun; 3(6):. PubMed ID: 32381551
[TBL] [Abstract][Full Text] [Related]
16. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
[TBL] [Abstract][Full Text] [Related]
17. HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3.
Chen JY; Chen YJ; Yen CJ; Chen WS; Huang WC
Oncotarget; 2016 Jan; 7(1):473-89. PubMed ID: 26595522
[TBL] [Abstract][Full Text] [Related]
18. Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.
Duvvuri U; George J; Kim S; Alvarado D; Neumeister VM; Chenna A; Gedrich R; Hawthorne T; LaVallee T; Grandis JR; Bauman JE
Clin Cancer Res; 2019 Oct; 25(19):5752-5758. PubMed ID: 31308059
[TBL] [Abstract][Full Text] [Related]
19. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
[TBL] [Abstract][Full Text] [Related]
20. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas.
Lee TL; Yeh J; Friedman J; Yan B; Yang X; Yeh NT; Van Waes C; Chen Z
Int J Cancer; 2008 May; 122(9):1987-98. PubMed ID: 18172861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
